Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia.

Baltajian K, Hecht JL, Wenger JB, Salahuddin S, Verlohren S, Perschel FH, Zsengeller ZK, Thadhani R, Karumanchi SA, Rana S.

Hypertens Pregnancy. 2014 Nov;33(4):427-39. doi: 10.3109/10641955.2014.926914.

PMID:
25062083
2.

Clinical characterization and outcomes of preeclampsia with normal angiogenic profile.

Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, Thadhani R, Karumanchi SA.

Hypertens Pregnancy. 2013 May;32(2):189-201. doi: 10.3109/10641955.2013.784788.

3.

Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.

Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T.

J Matern Fetal Neonatal Med. 2012 May;25(5):498-507. doi: 10.3109/14767058.2011.591461.

4.

Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia.

March MI, Geahchan C, Wenger J, Raghuraman N, Berg A, Haddow H, Mckeon BA, Narcisse R, David JL, Scott J, Thadhani R, Karumanchi SA, Rana S.

PLoS One. 2015 May 12;10(5):e0126815. doi: 10.1371/journal.pone.0126815.

5.

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE.

Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066.

6.

Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.

Govender N, Naicker T, Rajakumar A, Moodley J.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021.

PMID:
23806447
7.

Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A.

J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.

PMID:
22902831
8.

Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA.

Circulation. 2012 Feb 21;125(7):911-9. doi: 10.1161/CIRCULATIONAHA.111.054361.

9.

A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS.

J Matern Fetal Neonatal Med. 2009 Nov;22(11):1021-38. doi: 10.3109/14767050902994754.

10.

Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?

Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, Lim KH, Bdolah-Abram T, Epstein FH, Karumanchi SA.

Am J Obstet Gynecol. 2008 Apr;198(4):428.e1-6. doi: 10.1016/j.ajog.2007.10.783.

PMID:
18191808
11.

The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.

Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS.

J Matern Fetal Neonatal Med. 2008 May;21(5):279-87. doi: 10.1080/14767050802034545.

12.

Circulating angiogenic factors and placental abruption.

Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ.

Obstet Gynecol. 2006 Aug;108(2):338-44. Erratum in: Obstet Gynecol. 2006 Oct;108(4):1035.

PMID:
16880304
13.

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.

Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA.

J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23. doi: 10.1080/14767050701830480.

14.

Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.

Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR, Espinoza J, Gonçalves LF, Edwin S, Mazor M.

J Matern Fetal Neonatal Med. 2005 Jul;18(1):9-16.

PMID:
16105786
15.

Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.

Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M.

Obstet Gynecol. 2007 Jun;109(6):1368-74.

PMID:
17540809
16.

Angiogenic factors for the prediction of preeclampsia in high-risk women.

Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE.

Am J Obstet Gynecol. 2007 Sep;197(3):244.e1-8.

PMID:
17826405
17.

Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS.

J Matern Fetal Neonatal Med. 2011 Oct;24(10):1187-207. doi: 10.3109/14767058.2011.589932.

18.

Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1.

Bdolah Y, Elchalal U, Natanson-Yaron S, Yechiam H, Bdolah-Abram T, Greenfield C, Goldman-Wohl D, Milwidsky A, Rana S, Karumanchi SA, Yagel S, Hochner-Celnikier D.

Hypertens Pregnancy. 2014 May;33(2):250-9. doi: 10.3109/10641955.2013.858745.

PMID:
24304210
19.

Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.

Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS.

Am J Obstet Gynecol. 2013 Apr;208(4):287.e1-287.e15. doi: 10.1016/j.ajog.2013.01.016.

20.

Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia.

Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA.

Hypertension. 2012 Aug;60(2):451-8. doi: 10.1161/HYPERTENSIONAHA.112.195065.

Items per page

Supplemental Content

Support Center